ATE153536T1 - Hiv-induzierte synzytien blockierender anti-cd-4- antikörper - Google Patents

Hiv-induzierte synzytien blockierender anti-cd-4- antikörper

Info

Publication number
ATE153536T1
ATE153536T1 AT92903295T AT92903295T ATE153536T1 AT E153536 T1 ATE153536 T1 AT E153536T1 AT 92903295 T AT92903295 T AT 92903295T AT 92903295 T AT92903295 T AT 92903295T AT E153536 T1 ATE153536 T1 AT E153536T1
Authority
AT
Austria
Prior art keywords
synzytia
hiv
antibodies
induced
blocking anti
Prior art date
Application number
AT92903295T
Other languages
German (de)
English (en)
Inventor
Linda C Burkly
Patricia L Chisholm
David W Thomas
Margaret D Rosa
Joseph J Rosa
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE153536T1 publication Critical patent/ATE153536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92903295T 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4- antikörper ATE153536T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61854290A 1990-11-27 1990-11-27

Publications (1)

Publication Number Publication Date
ATE153536T1 true ATE153536T1 (de) 1997-06-15

Family

ID=24478147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903295T ATE153536T1 (de) 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4- antikörper

Country Status (12)

Country Link
US (1) US5871732A (enExample)
EP (1) EP0512112B1 (enExample)
JP (5) JPH05505112A (enExample)
AT (1) ATE153536T1 (enExample)
AU (1) AU662891B2 (enExample)
CA (1) CA2073031C (enExample)
DE (1) DE69126301T2 (enExample)
DK (1) DK0512112T3 (enExample)
ES (1) ES2101834T3 (enExample)
GR (1) GR3024274T3 (enExample)
OA (1) OA10079A (enExample)
WO (1) WO1992009305A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651970A (en) * 1993-03-19 1997-07-29 Allen; Allen D. Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics
DE4435950A1 (de) * 1994-10-07 1996-04-11 Hoechst Ag Copolymerisate mit cyclischen oder polycyclischen Monomeren mit einer speziellen Isomerenverteilung und deren Einsatz in Beschichtungsmitteln
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
AU3044697A (en) * 1997-06-24 1999-01-04 Norman Godin A composition for specific immunoprotection and method for obtaining said comp osition
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
JP2003533968A (ja) * 1999-09-03 2003-11-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
AU2003299085B2 (en) * 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
AU2007286451A1 (en) * 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP3067368A1 (en) 2007-04-27 2016-09-14 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
RU2531548C2 (ru) * 2008-09-29 2014-10-20 Биотест Аг Композиция для лечения заболевания
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
CN102321653B (zh) * 2011-07-18 2013-11-20 清华大学 人鼠嵌合型cd4质粒及其多抗在抑制hiv感染中的应用
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
JP6408487B2 (ja) 2012-12-18 2018-10-24 ザ ロックフェラー ユニバーシティ Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US11180555B2 (en) 2014-09-16 2021-11-23 Ubi Us Holdings, Llc. Antibodies directed against CD4 for the treatment and functional cure of HIV
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2016273213B2 (en) 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
AU2017312887A1 (en) 2016-08-13 2019-03-07 United BioPharma, Inc. Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
TWI845745B (zh) * 2019-08-19 2024-06-21 洛克菲勒大學 具改良藥物動力學之經酸鹼度依賴性抗原結合活性工程化之抗人類免疫缺乏病毒抗體
WO2021062546A1 (en) * 2019-10-01 2021-04-08 Taimed Biologics Inc. Use of ibalizumab for the treatment of hiv-2 infection
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
CN112500491B (zh) 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
JP2025510948A (ja) * 2022-03-31 2025-04-15 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ４特異的抗体構築物及び組成物ならびにその使用
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN117659192A (zh) * 2023-10-19 2024-03-08 深圳市福元生物科技有限公司 Cd4纳米抗体的制备及其应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652447A (en) * 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4515895A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human helper T cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4653020A (en) * 1983-10-17 1987-03-24 International Business Machines Corporation Display of multiple data windows in a multi-tasking system
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
EP0347435A4 (en) * 1987-09-04 1991-11-21 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
US4908203A (en) * 1987-09-09 1990-03-13 Johnson & Johnson Method for inducing HIV neutralizing antibodies using an internal image idiotope
WO1989009782A1 (en) * 1987-10-14 1989-10-19 United States Of America, Represented By The Secre New anti-receptor peptides and therapeutic agents
WO1990004978A1 (en) * 1988-11-01 1990-05-17 Becton Dickinson And Company Method of directing immune response to a viral binding site
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
EP0512112B1 (en) 1997-05-28
HK1007686A1 (en) 1999-04-23
JP2002356499A (ja) 2002-12-13
WO1992009305A1 (en) 1992-06-11
JPH05505112A (ja) 1993-08-05
OA10079A (en) 1996-12-18
DE69126301T2 (de) 1998-01-02
JP2005041859A (ja) 2005-02-17
CA2073031A1 (en) 1992-05-28
EP0512112A1 (en) 1992-11-11
ES2101834T3 (es) 1997-07-16
US5871732A (en) 1999-02-16
CA2073031C (en) 2002-10-01
GR3024274T3 (en) 1997-10-31
JP2007151556A (ja) 2007-06-21
AU662891B2 (en) 1995-09-21
DE69126301D1 (de) 1997-07-03
JP2007175055A (ja) 2007-07-12
AU9154391A (en) 1992-06-25
DK0512112T3 (da) 1997-09-29
JP4642035B2 (ja) 2011-03-02

Similar Documents

Publication Publication Date Title
DE69126301D1 (de) Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
ATE86636T1 (de) F antigene vom menschlichen immunodefizienz-virus und deren verwendungen.
DE69434811D1 (de) Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
CA2091263A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Okamoto et al. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432
DK0494294T3 (da) Bakterielle stressproteiner
JO1671B1 (en) New ways to diagnose tuberculosis
EP0252064A3 (en) Preparations active against pseudomonas aeruginosa infections, and process for their preparation
ATE142262T1 (de) Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat
AU6461594A (en) Induction of protection against viral infection
Panem et al. Renal deposition of alpha interferon in systemic lupus erythematosus
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ATE239502T1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
WO1991018618A3 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
Prümmer et al. Anti-interferon-γ antibodies in a patient undergoing interferon-γ treatment for systemic mastocytosis
SE9600436D0 (sv) Vaccine against hantavirus
Tyring et al. Antiviral action of murine interferons on heterologous cells
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time